We rely on your support for our independence, diversity and quality. Fair Observer is a 501(c)(3) independent nonprofit. We are not owned by billionaires or controlled by advertisers. We publish ...
Abstract: The decentralization mechanism provides manufacturers and distributors with greater customization and flexibility they need through Internet of Things (IoT)-based industrial collaboration ...
ATTR-cm is a rare heart condition that presents with similar symptoms as common heart conditions. This has led to a history of misdiagnosis or underdiagnosis of ATTR-cm. ATTR-cm is caused by the build ...
For people diagnosed with the most uncommon heart, condition transthyretin amyloid cardiomyopathy, there are many treatment options available such as medications and surgery. Your doctor will choose ...
With several disease-modifying therapies available for transthyretin amyloid cardiomyopathy (ATTR-CM) -- and more waiting in the wings -- choosing one has become a new challenge, with softer endpoints ...
MINNEAPOLIS, MN—Treatment with acoramidis (Attruby; BridgeBio Pharma) compared with placebo appears to reduce cumulative cardiovascular events by almost half among patients who have transthyretin ...
Over 31% of patients in the so-called Screening for Cardiac Amyloidosis with Nuclear Imaging in Minority Populations (SCAN-MP) study were women. Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) ...
BridgeBio (BBIO) Pharma presented initial outcomes from the ATTRibute-CM open-label extension study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions. ATTRibute-CM was ...
Background: Patients with transthyretin (ATTR) cardiac amyloid infiltration are increasingly diagnosed at earlier disease stages with no heart failure (HF) symptoms and a wide range of cardiac amyloid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results